Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Atherosclerosis
Atherosclerosis
Article
Statins and Insulin Resistance
Read time: 1h 1m 1s
About
Media
Watch time: 4m 53s
Watch time: 4m 57s
Watch time: 8m 2s
Watch time: 3m 25s
Watch time: 4m 43s
Watch time: 4m 14s
Watch time: 7m 48s
Watch time: 7m 44s
Watch time: 10m 34s
Watch time: 9m 40s
Articles
Everything in Moderation: Investigating the U-Shaped Link Between HDL Cholesterol and Adverse Outcomes
Citation:
US Cardiology Review 2019;13(1):49–53
- Views:
137
- Downloads:
0
Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS study
Citation:
European Cardiology Review 2018;13(2):115–8.
- Views:
679
- Downloads:
0
Using Pharmacogenetic Testing or Platelet Reactivity Testing to Tailor Antiplatelet Therapy: Are Asians Different from Caucasians?
Citation:
European Cardiology Review 2018;13(2):112–4.
- Views:
259
- Downloads:
0
Characteristics of Lipid Profile of LPL Deficiency in Japan – Comparison with Non-LPL Deficiency
Citation:
European Cardiology Review 2018;13(2):132.
- Views:
67
- Downloads:
0